FMO5 and cancer: In addition, ROS produced by NADPH oxidase-expressing malignant myeloid cells [9], [10] or by tumor-infiltrating macrophages [11]–[18] have been proposed to contribute to the state of NK cell and T cell dysfunction in several forms of cancer, which is the background to the use of ROS inhibitors in cancer immunotherapy [19]–[21].